Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | ANPEP | P15144 | 1/20 | 0.37 |
| ▸ | MMP1 | P03956 | 2/20 | 0.36 |
| ▸ | MMP2 | P08253 | 2/20 | 0.36 |
| ▸ | MMP9 | P14780 | 2/20 | 0.36 |
| ▸ | MMP8 | P22894 | 2/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL464668 | 1.00 | SIGMAR1 (0.39) | SIGMAR1CHRNB2CHRNA4OPRM1ANPEP | |
| SCHEMBL16770603 | 1.00 | SIGMAR1 (0.39) | SIGMAR1CHRNB2CHRNA4OPRM1ANPEP | |
| SCHEMBL13616986 | 1.00 | SIGMAR1 (0.39) | SIGMAR1CHRNB2CHRNA4OPRM1ANPEP | |
| SCHEMBL22768719 | 1.00 | SIGMAR1 (0.39) | SIGMAR1CHRNB2CHRNA4OPRM1ANPEP | |
| SCHEMBL24821527 | 0.85 | SHBG (0.41) | SIGMAR1CHRNB2CHRNA4OPRM1 | |
| SCHEMBL3326902 | 0.82 | OPRM1 (0.38) | OPRM1ANPEP | |
| SCHEMBL13299010 | 0.82 | OPRM1 (0.38) | OPRM1ANPEP | |
| SCHEMBL18950788 | 0.82 | SIGMAR1 (0.40) | SIGMAR1OPRM1 | |
| SCHEMBL25675768 | 0.81 | PDPK1 (0.44) | — | |
| SCHEMBL18976626 | 0.78 | CHRNB2 (0.40) | SIGMAR1CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024137607-A1 | THIADIAZOLE DERIVATIVES AS INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF | VENTUS THERAPEUTICS U.S., INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| US-11795159-B2 | Compounds for the treatment of SARS | PURDUE RESEARCH FOUNDATION (US) | 2023-10-24 | — | — | US | disclosed |
| US-20230192671-A1 | COMPOUNDS FOR THE TREATMENT OF SARS | PURDUE RESEARCH FOUNDATION | 2023-06-22 | — | — | US | disclosed |
| US-20220411401-A1 | COMPOUNDS FOR THE TREATMENT OF SARS | PURDUE RESEARCH FOUNDATION | 2022-12-29 | — | — | US | disclosed |
| WO-2015078374-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2015-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11795159-B2 | Compounds for the treatment of SARS | ACE2, ACE, SARS1 | SIGMAR1 3060/4885CHRNB2 4004/4885CHRNA4 4459/4885 |
| US-20230192671-A1 | COMPOUNDS FOR THE TREATMENT OF SARS | ACE2, ACE, SARS1 | SIGMAR1 3060/4885CHRNB2 4004/4885CHRNA4 4459/4885 |
| US-20220411401-A1 | COMPOUNDS FOR THE TREATMENT OF SARS | ACE2, ACE, SARS1 | SIGMAR1 3060/4885CHRNB2 4004/4885CHRNA4 4459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.